Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc.AUPH · Entity 4463 | Chief Commercial Officer | March 02, 2022 | March 04, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aurinia Pharmaceuticals Inc.
Report date March 02, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,495 |
Ending reported balance
After 2022-03-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-02 · Grant · Acquired 8,500 · Balance 16,700 F1: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration. Row 2 · 2022-03-02 · Sale · Disposed 3,205 · Balance 13,495 F2: Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 104,080 |
Reported balance
After 2022-03-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-02 · Grant · Acquired 104,080 · Balance 104,080 F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.01 · Expires 2032-03-02 | Direct | 178,063 |
Reported balance
After 2022-03-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-03-02 · Grant · Acquired 178,063 · Balance 178,063 F4: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration.
F2: Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards.
F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date.
F4: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2022 Filed Mar 4, 2022 21:11 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantStock Option (right to buy) · Derivative | 178,063 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0001628280-22-005124 · wf-form4_164642829060367.xml · derivative · entry 4 Colao Massimilano · CIK 0001837645 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,063 Underlying: Common Stock · 178,063 shares Expires 2032-03-02 F4 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:11 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantRestricted Stock Unit · Derivative | 104,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005124 · wf-form4_164642829060367.xml · derivative · entry 3 Colao Massimilano · CIK 0001837645 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,080 Underlying: Common Shares · 104,080 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F3 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F3 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:11 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 3,205 | $12.01 | $38,492.05 |
DisclosureSEC source: 0001628280-22-005124 · wf-form4_164642829060367.xml · nonDerivative · entry 2 Colao Massimilano · CIK 0001837645 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,495 F2 · shares: Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:11 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005124 · wf-form4_164642829060367.xml · nonDerivative · entry 1 Colao Massimilano · CIK 0001837645 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,700 F1 · shares: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.